Bahrain: Over 3,000 volunteers participated in COVID-19 vaccine trial

- Advertisement -

More than 3,000 volunteers, including citizens and residents, have participated in the phase III clinical trial for a COVID-19 inactivated vaccine so far.

The National Medical Taskforce for Combating Coronavirus (COVID-19) is overseeing the trial of the potential vaccine at the Bahrain International Exhibition and Convention Centre (BIECC), as part of its efforts to limit the spread of the pandemic.

The participants highlighted the importance of taking part in the clinical trials to contribute to efforts to reach a vaccine to the pandemic from which the entire world is suffering, affirming that their experience was positive, as they reported no health problems or side effects.

READ  Bahrain: MOH Announces Guidelines for Salons, Barbershops

In this regard, Dr. Amal Al-Ghanim stressed the importance of taking the potential vaccine, describing the third phase of the clinical trial as successful and secure.

She asserted that the National Medical Taskforce for Combating COVID-19 will not recommend the vaccine only after its confirmation, study and collection of all information related to it, expressing confidence in the National Medical Taskforce’s efforts and measures.

She emphasised that the recent increase in the number of infected cases necessitates the need to find a vaccine that ends the spread of the virus.

READ  Bahrain reports 285 new cases; Total cases reach 9,977

Conducted in collaboration with the Abu-Dhabi based G42 Healthcare using a vaccine developed by Sinopharm CNBG the world’s sixth largest producer of vaccines in the world, the potential vaccine will be tested on about 6,000 volunteers who meet the required medical criteria.

 Open to volunteers above the age of 18 who do not suffer from chronic or underlying conditions, phase III of clinical trials has been approved by the National Health Regulatory Authority (NHRA) following the success of its phase I and phase II clinical trials across China.

Comments

- Advertisement -